Clinical Report: Beyond Morphology and IHC

Overview

This report discusses the challenges in diagnosing cancers of unknown primary (CUP) and the potential of molecular testing to enhance tumor origin detection and guide treatment decisions, emphasizing its role in identifying actionable biomarkers.

Background

Cancers of unknown primary (CUP) present significant diagnostic challenges, often leaving clinicians without clear treatment pathways. Traditional methods, including morphology and immunohistochemistry (IHC), may fail to provide definitive answers, necessitating the exploration of molecular testing methods such as next-generation sequencing to identify actionable biomarkers. Understanding the role of molecular profiling is crucial for improving patient outcomes in these complex cases.

Data Highlights

No numerical data provided in the source material, which limits the ability to quantify findings.

Key Findings

• Molecular testing can uncover actionable biomarkers in approximately one-third of patients with CUP.
• Diagnostic ambiguity often arises from poor differentiation, conflicting IHC results, and limited tissue samples.
• Multidisciplinary discussions are essential for determining the appropriateness of molecular testing in guiding treatment decisions.
• Systemic therapy decisions may hinge on molecular profiling, especially in cases with multiple lesions.
• Recent trials indicate that molecularly guided therapy can improve progression-free survival in unfavorable CUP cases.

Clinical Implications

Clinicians should consider molecular testing for patients with CUP or difficult-to-classify tumors, particularly when systemic therapy is indicated, such as targeted therapies based on specific genomic alterations. A multidisciplinary approach is recommended to ensure that testing decisions align with patient care goals and treatment options.

Conclusion

Molecular testing represents a promising avenue for improving the diagnosis and management of cancers of unknown primary, emphasizing the need for a shift towards more personalized treatment strategies that integrate molecular profiling into routine practice.

References

1. SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025) - PMC
2. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
3. the pathologist — Virtual Staining in the Tumor Microenvironment
4. Blood Cancer Journal — Characterization of Spatial Phenotypes in Nodular Lymphocyte Predominant Hodgkin Lymphoma and T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
5. Acta Neuropathologica — Targeted Identification of H3K27M Mutation in Fixed Tissue Samples from High-Grade Astrocytomas
6. Journal of Neuro-Oncology — Distribution of Tumor and Immune Cells in the Core and Peripheral Regions of IDH Wildtype Glioblastoma
7. Virtual Staining in the Tumor Microenvironment
8. Characterization of Spatial Phenotypes in Nodular Lymphocyte Predominant Hodgkin Lymphoma and T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
9. Targeted Identification of H3K27M Mutation in Fixed Tissue Samples from High-Grade Astrocytomas
10. SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025) - PMC
11. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
12. The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary: A Systematic Review - PubMed